http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 16:01:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Marvel+Biosciences+plans+private+placement+of+up+to+%243M/26779543.html <p>Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) announced a non-brokered private placement offering of up to 20,000,000 units at $0.15 per unit, seeking gross proceeds of up to $3,000,000, according to a press release dated July 16, 2026.</p> <p>The offering has a minimum of 10,000,000 units for gross proceeds of $1,500,000. Each unit consists of one common share and one warrant, with each warrant exercisable at $0.20 per share beginning 61 days after closing and expiring one year from the closing date. The warrants may be accelerated if the volume weighted average trading price of the common shares on the TSX http://www.streetinsider.com/Equity+Offerings/Marvel+Biosciences+plans+private+placement+of+up+to+%243M/26779543.html Thu, 16 Jul 2026 16:01:13 -0400 MBCOF http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html <p>Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("<b>Marvel</b>" or the "<b>Company</b>") is pleased to announce that it intends to complete a non&#8208;brokered private placement offering (the "<b>Offering</b>") of units of the Company ("<b>Units</b>") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of 20,000,000 Units, for gross proceeds of up to $3,000,000.</p><p>Each Unit will consist of one common share of the Corporation ("<b>Common Share</b>") and one Common Share purchase warrant ("<b>Warrant</b>"). Each Warrant http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html Thu, 16 Jul 2026 16:00:00 -0400 MBCOF http://www.streetinsider.com/Newsfile/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html <p>Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("<b>Marvel</b>" or the "<b>Company</b>") is pleased to announce that it intends to complete a non&#8208;brokered private placement offering (the "<b>Offering</b>") of units of the Company ("<b>Units</b>") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of 20,000,000 Units, for gross proceeds of up to $3,000,000.</p><p>Each Unit will consist of one common share of the Corporation ("<b>Common Share</b>") and one Common Share purchase warrant ("<b>Warrant</b>"). Each Warrant http://www.streetinsider.com/Newsfile/Marvel+Biosciences+Announces+Private+Placement+for+up+to+%243.0+Million/26779530.html Thu, 16 Jul 2026 16:00:00 -0400 MBCOF http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Press+Releases/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html <p align="justify">CALGARY, Alberta, June 26, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively<strong> “Marvel” </strong>or the<strong> “Company”</strong>), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, is pleased to announce one of their collaborators from the iBraiN Institute in Tours France, Dr. Jérôme Becker, will give an oral presentation at the 3rd European Purine Meeting, taking place in Bordeaux, France, from July 1 to 3, 2026. Marvel is also proud to support the meeting as a conference gold sponsor.</p> <p http://www.streetinsider.com/Globe+Newswire/New+Autism+Research+to+be+Presented+at+European+Purine+Scientific+Meeting/26694865.html Fri, 26 Jun 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.</p> <p>MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.</p> <p>"We are continuing to extend our composition of http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+receives+Australian+patent+allowance+for+MB-204/26614131.html Mon, 08 Jun 2026 07:00:46 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html <p align="justify">CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026.  The patent is expected to be granted shortly after August 28, 2026.</p> <p align="justify">The Australian notice of allowance further strengthens Marvel&apos;s global composition-of-matter patent portfolio for MB-204, reinforcing the Company&apos;s intellectual property position as it advances http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html Mon, 08 Jun 2026 07:00:00 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html <p align="justify">CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026.  The patent is expected to be granted shortly after August 28, 2026.</p> <p align="justify">The Australian notice of allowance further strengthens Marvel&apos;s global composition-of-matter patent portfolio for MB-204, reinforcing the Company&apos;s intellectual property position as it advances http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html Mon, 08 Jun 2026 07:00:00 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html <p align="justify">CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026.  The patent is expected to be granted shortly after August 28, 2026.</p> <p align="justify">The Australian notice of allowance further strengthens Marvel&apos;s global composition-of-matter patent portfolio for MB-204, reinforcing the Company&apos;s intellectual property position as it advances http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html Mon, 08 Jun 2026 07:00:00 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html <p align="justify">CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026.  The patent is expected to be granted shortly after August 28, 2026.</p> <p align="justify">The Australian notice of allowance further strengthens Marvel&apos;s global composition-of-matter patent portfolio for MB-204, reinforcing the Company&apos;s intellectual property position as it advances http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html Mon, 08 Jun 2026 07:00:00 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html <p align="justify">CALGARY, Alberta, June 08, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel</strong> <strong>Biosciences</strong> <strong>Corp.</strong> <strong>(TSXV:</strong> <strong>MRVL</strong> <strong>|</strong> <strong>OTC:</strong> <strong>MBCOF</strong>), and its wholly owned subsidiary, Marvel Biotechnology Inc.<strong> (collectively the “Company” or “Marvel”),</strong> a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026.  The patent is expected to be granted shortly after August 28, 2026.</p> <p align="justify">The Australian notice of allowance further strengthens Marvel&apos;s global composition-of-matter patent portfolio for MB-204, reinforcing the Company&apos;s intellectual property position as it advances http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Receives+Notice+of+Allowance+for+Australian+Patent+Application+Covering+Composition+of+Matter+for+its+Lead+Therapeutic+Candidate+MB-204/26614112.html Mon, 08 Jun 2026 07:00:00 -0400 A.19022412 A.36078215 MBCOF MRVL O.02555813 O.19806361 O.46356335